A multi-site break through cancer trial: Phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (trial in progress) Meeting Abstract

  

Authors:	Issa, G. C.; Ambinder, A. J.; Xiao, W.; Manalis, S.; Shalek, A. K.; Gondek, L. P.; Kentsis, A.; Short, N. J.; Daver, N.; Ning, J.; Xiao, L.; Hemann, M.; Chen, K.; Patel, K. P.; Bachireddy, P.; Lane, A. A.; Konopleva, M.; Abdel-Wahab, O.; Molldrem, J. J.; Levine, R. L.; Levis, M. J.; Stone, R. M.; Andreeff, M.; Ravandi, F.; Goldberg, A. D.; Garcia, J. S.
Abstract Title:	A multi-site break through cancer trial: Phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (trial in progress)
Meeting Title:	66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	144
Issue:	Suppl. 1
Meeting Dates:	2024 Dec 7-10
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2024-11-05
Start Page:	42652
Language:	English
ACCESSION:	WOS:001411951200047
DOI:	10.1182/blood-2024-201582
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/227037